Methods: RCT’s simplicity advantage

In “Assessing the case for social experiments,” James Heckman and Jeffrey Smith warn against mistaking the apparent simplicity of randomized controlled trials for actual simplicity. For,

READ MORE

The overscreening never seems to end

From JAMA Internal Medicine, “Cancer Screening Rates in Individuals With Different Life Expectancies“: Importance: Routine cancer screening has unproven net benefit for patients with limited

READ MORE

The quality of Medicare Advantage

The following originally appeared on The Upshot (copyright 2014, The New York Times Company). Medicare Advantage plans — private plans that serve as alternatives to the traditional,

READ MORE

Antibiotic prizes

From the New Yorker article today on the economics of Ebola (introducing a new word, Ebolanomics): What people in the West need, health officials agree, is

READ MORE

Writing for Science and the One Percent

John Ionnadis and colleagues have a remarkable finding about scientific authors: we estimated that there are 15,153,100 publishing scientists (distinct author identifiers) in the period

READ MORE

Methods: There is no gold standard

In “Instruments, Randomization, and Learning about Development,” Angus Deaton pulls no punches. He’s just as brutal, blunt, and precise about pitfalls and misuse of instrumental variables

READ MORE
Subscribe

Email Address*